BioLamina is a series b startup. 1 investor tracked.
BioLamina is a company founded in 2008 headquartered in Sweden. Its most recent tracked round is Series B. Brouky records 2 investors associated with the company.
BioLamina provides full-length human recombinant laminin proteins that serve as biologically relevant cell culture matrices, supporting the expansion of pluripotent stem cells and the differentiation and maintenance of specialized cell types for research and therapeutic applications.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.